The BNP metabolism is mainly non-renal, mediated by the binding to the natriuretic peptide receptor type C (NPR-C) and through proteolysis by neutral endopeptidases; thus, its concentration in CKD patients is less affected by eGFR, without the need of a correction of values in patients with CKD stages 1–2 [20]. Here, NPPB is linked to chronic kidney disease.